Prostate cancer is the most commonly diagnosed cancer among men and the second leading cause of cancer-related deaths among men in the US. 
for his age, and denied any bothersome symptoms. His physical examination, including digital rectal examination (DRE), was unremarkable.
A 12-core prostate biopsy was then performed. Pathologic examination showed that two of the 12 cores were involved on the left with Gleason 3+3 (moderately differentiated) and <50% of cores were positive, and no peri-neural invasion was noted. While not routinely recommended, as per patient request imaging studies (computed tomography [CT] scan of the chest/abdomen/pelvis and bone scans) were obtained and were unremarkable. His urologist recommended active surveillance for his prostate cancer. However, the patient was shocked, and said, 'What do you mean? I have cancer and we are going to observe it?' The urologist then explained the rationale of observation. However, the patient was not satisfied and requested a medical oncology opinion for discussion of treatment options. This is not an uncommon scenario encountered in medical oncology clinics. In order to make a treatment decision, two key factors need to be considered: risk stratification and life expectancy (age and comorbidities).
Risk Stratification for Prostate Cancer
The risk for disease progression following definitive therapy for localized prostate cancer can be broadly classified into four categories: very low risk, low risk, moderate risk, and high risk, as outlined in Table 1 . 10 Low risk is defined as T1c-T2a, Gleason score ≤6, and PSA ≤10ng/ml; intermediate risk is defined as T2b, Gleason 7, or PSA 10.1-20ng/ml, and no high-risk features; and high risk is defined as Gleason 8-10, or T2b or greater, PSA >20ng/ml, or pre-treatment PSA velocity >2ng/ml/year.
Retrospective studies have reported that the risk for death from prostate cancer after definitive surgery for localized prostate cancer is much higher among patients with high-risk (hazard ratio [HR] 11.5; p<0.0001) or intermediate-risk disease (HR 6.3; p<0.0001) compared with patients at low risk, 11 and this risk stratification is utilized in the National Comprehensive Cancer Network (NCCN) guidelines (www.nccn.org) for prostate cancer as well. Given the concerns of overtreatment of localized prostate cancer, in the 2010 update the NCCN panel added another category: very low risk, defined as T1c,
Gleason score ≤6, PSA ≤10ng/ml, fewer than three core biopsies positive, ≤50% in each core, and PSA density <0.15ng/ml/g (such as the patient in this case study).
Life Expectancy (Age and Presence of Comorbidities)
Not all prostate cancers are lethal; in fact, a large number of men with localized prostate cancer die with it, rather than of it. 12, 13 i.e. small, organ-confined prostate cancer. [27] [28] [29] [30] [31] [32] [33] It is suggested that PSA velocity rather than absolute value of PSA might be helpful in predicting presence of aggressive prostate cancer. 34, 35 Recent studies have also suggested that besides age, PSA, and initial Gleason score, the results of the first repeat prostate biopsy are also an important predictor of disease progression. [36] [37] [38] [39] Another key factor that should be considered in decision-making is patient preference and beliefs. Often the fear of the word 'cancer' is out of proportion to the real threat of cancer. The patient may have a loved one who experienced a terrible death from cancer and consequently he is afraid he is going to have a painful death as well.
Listening carefully to the patient, understanding his concerns, and addressing them in an effective and rational fashion is thus of paramount importance in decision-making.
The NCCN recommends that active surveillance is appropriate for men with very-low-risk prostate cancer and a life expectancy of less than 20 years, or those with low-risk disease and a life expectancy of less than 10 years. The recommended follow-up includes PSA checks every three to six months, DRE every six to 12 months, and prostate biopsy after 18 months if initial biopsy had greater than 10 cores, or if any abnormality is noted on PSA or DRE. Prostate cancer progression warranting treatment is to be considered if PSA doubling time is less than three years, a primary Gleason score of 4 or 5 is found on repeat biopsy, or carcinoma is detected to a greater extent or in greater number in repeat biopsies.
The advantages of active surveillance include reduced time spent away from work and family due to therapy as well as avoidance of potential side effects of a therapy that was not needed. 40 For example, RP can have a significant impact on urinary and sexual function, while ADT can lead to osteopenia, weight gain, and increased risk for cardiovascular events.
41,42
The disadvantages of active surveillance include the potential for greater progression of disease than anticipated, the chance that the subsequent treatment may be more complex and invasive, increased patient anxiety, and the need for close follow-up, including prostate biopsies.
In summary, risk stratification of prostate cancer and the life expectancy of the individual person in consideration, along with patient preference, are crucial in clinical decision-making for low-risk localized prostate cancer. Our patient (case study 1) has very-low-risk prostate cancer and a life expectancy of about 10-15 years. Thus, the prostate cancer is most likely clinically insignificant and will not pose a significant health problem.
Therefore, active surveillance with regular PSA, DRE, and prostate biopsy would be appropriate and is the recommended treatment.
Summary for Case Study 1
This was discussed with the patient. The relevant data were reviewed, including the concept that while he did have prostate cancer, the cancer was likely not to have a significant impact clinically, cause bothersome symptoms, or shorten his survival. Moreover, it was emphasized that he would be followed closely to monitor for any progression of disease and/or development of symptoms. The fears and anxiety of the patient were allayed, and he agreed to participate in active surveillance for his localized prostate cancer.
Case Study 2
A 60-year-old pharmacist was found to have a rise in PSA on his yearly screenings from 2.9 to 6.5ng/ml in the past year. He was otherwise in good health. His physical examination, including DRE, was unremarkable. Pathologic examination of the 12-core prostate biopsy showed that eight of the 12 cores were involved on the left with Gleason 4+5, >50% of cores were positive, and peri-neural invasion was noted.
CT scan of the chest/abdomen/pelvis was unremarkable, except for possible seminal vesicle invasion. He was then seen by a radiation oncologist who recommended external-beam radiation therapy (RT), and also referred him to a medical oncologist for consideration of neoadjuvant and adjuvant hormonal therapy. 44, 45 ADT is the first-line therapy for metastatic prostate cancer and has received considerable attention in the adjuvant setting as well, as outlined below and in Table 2 .
Role of Androgen Deprivation Therapy in

Timing of Androgen Deprivation Therapy After Radiation Therapy
Immediate versus Deferred Androgen Deprivation Therapy
In p=0.0004) compared with those assigned to deferred ADT (n=51). It should be noted that the duration of ADT was not optimally defined in the study (goserelin was recommended to be used continually), and the study results do not address the appropriateness of adjuvant ADT in lymph-node-negative, high-risk localized prostate cancer. When first published, this study received criticism for its small sample size and poor methodology. 57 Moreover, the long-term effects of ADT on bone or cardiovascular risk were not ascertained prospectively in a systematic fashion, as the trial was conceived in the 1980s and at that time these adverse effects (osteopenia and cardiovascular risk) were not well recognized.
A subsequent publication did address some of the major concerns. 56 It should be recognized that this is the only RCT on adjuvant ADT for lymph-node-positive prostate cancer after RP. 56 Moreover, the treatment of biochemical recurrence (rise in PSA) after RP (or even RT) without radiologic evidence of metastatic disease is currently controversial. 58 Thus, long-term ADT should be considered among men with lymph-node-positive prostate cancer after RP.
Neoadjuvant Androgen Deprivation Therapy Before Radical Prostatectomy
A few studies have also evaluated the role of neoadjuvant ADT before RP.
In a large clinical trial, 402 men with localized prostate cancer (T2-T3) were randomized to neoadjuvant ADT in the form of LHRH analog (goserelin) plus flutamide for three months followed by RP, versus RP alone. 59 After four years of follow-up, the authors reported no difference in survival between the two arms. However, the neoadjuvant ADT arm had higher clinical and pathologic downstaging (p<0.01), a lower number of positive margins (p=0.01), and a lower local recurrence for cT2 tumors (p=0.03) but
Genitourinary Cancer After a median follow-up of 7.7 years, the authors reported no difference in overall survival or disease-free survival between the two groups. Thus, use of adjuvant anti-androgen monotherapy after RP or RT is discouraged.
Role of Adjuvant Chemotherapy
Currently, docetaxel is the only approved chemotherapy that has been shown to improve survival in metastatic prostate cancer, and is the first-line therapy for metastatic castrate-resistant prostate cancer. 63, 64 While no chemotherapy regimen has an established role as adjuvant The use of ADT, particularly long-term, is associated with a significant increase in adverse events including increase incidence of hot flashes, sexual dysfunction, cognitive changes, mood swings, osteopenia (bone loss), weight gain, diabetes, and potential for increased risk for cardiovascular disease. 41, 42, 65, 66 The use of long-term ADT, particularly among the elderly and men with baseline osteopenia (such as our patient), has been associated with up to a 50% increase in fracture risk. 67 In such patients, the use of agents that could slow this process or potentially even reverse bone loss should be considered, as discussed below.
Bisphosphonates
A number of small clinical trials have evaluated the role of bisphosphonates, particularly pamidronate and zoledronic acid, in the prevention of bone loss among prostate cancer patients receiving ADT. [68] [69] [70] [71] [72] Universally, the studies have reported that bisphosphonates (such as zoledronic acid 4mg every three months intravenously [IV]) can effectively improve bone mineral density (BMD) after one year of treatment. [68] [69] [70] [71] [72] [73] [74] [75] However, the ability to reduce fractures is less clear.
Moreover, ostenecrosis of the jaw is a rare but serious adverse effect of bisphosphonates, and thus the risks and benefits of bisphosphonates should be carefully weighed before its use.
RANKL Inhibitors
Denosumab is a fully human antibody against receptor activator of nuclear factor kappa-B ligand (RANKL), which plays an important role in osteoclast formation and function. 76 In an RCT, 1,468 men with localized prostate cancer on ADT were randomized to subcutaneous denosumab (60mg every six months) or placebo. 77 The authors reported that the BMD of the lumbar spine at the end of two years was significantly higher in the denosumab group compared with placebo (5.6% increase versus 1.0% loss; p<0.001), and men in the denosumab arm had a lower For men who have baseline osteopenia (such as our patient) or who show signs of reduced BMD during follow-up, agents that can improve bone density, such as bisphosphonates, might be considered. Our patient was interested in receiving long-term ADT, and thus use of bisphosphonates to prevent/reduce osteopenia was recommended.
We also recommended lifestyle modification (physical activity, calcium, and vitamin D supplementation) as these not only can reduce bone loss, but may have other beneficial effects as well.
Key Points About Localized Prostate Cancer a Medical Oncologist Should Know
• The majority of prostate cancers diagnosed are clinically localized prostate cancers, with clinical stage T1c being the most common.
• Medical oncologists are increasingly being asked to provide input on localized prostate cancer, particularly related to active surveillance and neoadjuvant and adjuvant therapies, such as ADT and chemotherapy.
• Active surveillance is appropriate for men with low-risk disease and a life expectancy less than 10 years.
• Adjuvant ADT after RT is appropriate for men with high-risk disease and a life expectancy greater than 10 years.
• Adjuvant ADT after RP is appropriate for men with high-risk disease and positive lymph nodes after RP.
• The management of men with biochemical recurrence (rising PSA)
after RP or RT and no radiological evidence of metastatic disease is controversial.
• Long-term ADT therapy can be associated with adverse effects including hot flashes, sexual dysfunction, weight gain, diabetes, cardiovascular disease, and bone loss. Lifestyle modification (such as physical activity) should be encouraged among all patients, and in men who have osteopenia or osteoporosis (at baseline or during followup), bone agents such as bisphosphonates should be considered.
• Men with high-risk, locally advanced cancers should be encouraged to participate in clinical trials. n
